| Next 10 |
Ad
ESPR News and Press Esperion Therapeutics Inc.
News | Esperion Therapeutics Inc. (NASDAQ:ESPR)
-
2024-12-02 14:40:10 ET DENVER, Colo., Dec 02, 2024 ( 247marketnews.com )- MoBot’s recent alerts included; Senti Biosciences (NASDAQ: SNTI ), Ocean Power (NYSE: OPTT ), KULR (NYSE: KULR ), ParaZero Technologies (NASDAQ: PRZO ), &#x...
-
ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and car...
-
2024-11-26 09:50:46 ET More on Esperion Therapeutics Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript Esperion Therapeutics Q3 2024 Earnings Preview Seeking Alpha’s Quant...
-
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for t...
-
ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36 th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET. The live webcast can be accessed on th...
-
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of an an...
-
2024-11-14 09:00:01 ET Gradually lowering inflation and reducing borrowing rates have opened new and exciting doors for growth stocks. With a positive economic outlook, investors could keep a watchful eye on Esperion Therapeutics (ESPR), AngioDynamics (ANGO), and Fathom Holdings (FTHM) to...
-
2024-11-13 02:08:21 ET Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and s...
-
2024-11-07 13:35:51 ET Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call November 7, 2024 08:00 ET Company Participants Alina Venezia - Director, Investor Relations Sheldon Koenig - President and Chief Executive Officer Ben Halladay - Chief Financial Offic...
-
2024-11-07 06:03:37 ET More on Esperion Therapeutics Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs Esperion Therapeutics: Strategically Positioned To Grow Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript Esper...
Stock Information
Get ESPR Alerts
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
Ad
-
2024-12-02 14:40:10 ET DENVER, Colo., Dec 02, 2024 ( 247marketnews.com )- MoBot’s recent alerts included; Senti Biosciences (NASDAQ: SNTI ), Ocean Power (NYSE: OPTT ), KULR (NYSE: KULR ), ParaZero Technologies (NASDAQ: PRZO ), &#x...
-
ANN ARBOR, Mich., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications that reduce low-density lipoprotein cholesterol (LDL-C) and car...
-
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for t...